PDF (3284K)
摘要
骨关节炎(osteoarthritis,OA)是一种以关节疼痛、功能障碍和软骨退变为主要特征的慢性疾病,目前仍缺乏能够有效改变其疾病进程的治疗手段。近年来,随着免疫学、分子生物学及干细胞与基因工程技术的进展,OA 的治疗研究不断推进。特异性靶向药物与非特异性抗炎药物在部分临床试验中表现出一定的抗炎或镇痛作用,但整体疗效有限且存在安全性顾虑。与此同时,免疫治疗、细胞治疗和基因治疗等新型技术为 OA 干预提供了新的思路,并在抑制炎症、保护软骨及改善疼痛方面显示出潜在优势,但其长期安全性、疗效稳定性及患者分层策略仍需进一步明确。未来,OA 的治疗有望向精准分型、联合干预、局部长效免疫调节以及新型药物递送方向发展。本综述总结了相关研究进展,为未来 OA 治疗策略优化提供参考。
Abstract
Osteoarthritis (OA) is a chronic condition characterized by joint pain, functional impairment, and degeneration of articular cartilage. Currently, there remains a lack of effective treatments capable of altering the disease progression. In recent years, advances in immunology, molecular biology, stem cell technology, and genetic engineering have driven forward research on OA therapies. Although targeted agents and non-specific anti-inflammatory drugs have shown certain anti-inflammatory or analgesic effects in some clinical trials, their overall efficacy remains limited and safety concerns persist. Meanwhile, emerging approaches such as immunotherapy, cell-based therapy, and gene therapy offer novel strategies for OA intervention, showing potential advantages in suppressing inflammation, preserving cartilage, and alleviating pain. However, issues such as long-term safety, durability of therapeutic effects, and patient stratification require further clarification. In the future, OA treatment is expected to evolve toward precise phenotyping, combined interventions, localized long-term immunomodulation, and innovative drug delivery approaches. This review summarizes recent advances in the field to provide insights for optimizing future therapeutic strategies for OA.
关键词
Key words
[Author(id=1330571805882912863, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=gkys0722@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571805941633123, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, authorId=1330571805882912863, language=EN, stringName=Zishun GAO, firstName=Zishun, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1 Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, Gansu, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571805983576165, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, authorId=1330571805882912863, language=CN, stringName=高自顺, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1 甘肃省中医院,兰州 730050,甘肃, bio={"content":"高自顺,男,硕士,住院医师,研究方向:骨关节及手足骨科疾病。E-mail:gkys0722@163.com
"}, bioImg=null, bioContent=高自顺,男,硕士,住院医师,研究方向:骨关节及手足骨科疾病。E-mail:gkys0722@163.com
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571805731917908, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, xref=1, ext=[AuthorCompanyExt(id=1330571805748695126, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, companyId=1330571805731917908, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1 Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, Gansu, China), AuthorCompanyExt(id=1330571805761278040, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, companyId=1330571805731917908, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1 甘肃省中医院,兰州 730050,甘肃)])]), Author(id=1330571806029713513, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571806088433774, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, authorId=1330571806029713513, language=EN, stringName=Yunxia LI, firstName=Yunxia, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2 Lanzhou University, Lanzhou 730000, Gansu, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571806134571122, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, authorId=1330571806029713513, language=CN, stringName=李云霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2 兰州大学,兰州 730000,甘肃, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571805807415386, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, xref=2, ext=[AuthorCompanyExt(id=1330571805824192604, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, companyId=1330571805807415386, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2 Lanzhou University, Lanzhou 730000, Gansu, China), AuthorCompanyExt(id=1330571805836775517, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330558536279470988, companyId=1330571805807415386, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2 兰州大学,兰州 730000,甘肃)])])]
高自顺,李云霞.
骨关节炎免疫治疗及新型技术研究进展[J].
中国临床药理学与治疗学, 2026, 31(9): 1286-1296 DOI:10.12092/j.issn.1009-2501.2026.09.015
| [1] |
中国骨关节炎诊疗指南专家组, 中国老年保健协会疼痛病学分会. 中国骨关节炎诊疗指南 (2024 版)[J].中华疼痛学杂志, 2024, 20(3): 323-338.
|
| [2] |
Duong V, Oo WM, Ding C, et al. Evaluation and treatment of knee pain: a review[J].JAMA, 2023, 330(16): 1568-1580.
|
| [3] |
Jin X, Jones G, Cicuttini F, et al. Effect of vitamin D supplementation on tibial cartilage volume and knee pain among patients with symptomatic knee osteoarthritis: a randomized clinical trial[J].JAMA, 2016, 315(10): 1005-1013.
|
| [4] |
Yang G, Wang J, Liu Y, et al. Burden of knee osteoarthritis in 204 countries and territories, 1990-2019: results from the global burden of disease study 2019[J].Arthritis Care Res (Hoboken), 2023, 75(12): 2489-2500.
|
| [5] |
Jia S, Liang R, Chen J, et al. Emerging technology has a brilliant future: the CRISPR-Cas system for senescence, inflammation, and cartilage repair in osteoarthritis[J].Cell Mol Biol Lett, 2024, 29(1): 64.
|
| [6] |
Ma CH, Lv Q, Yu YX, et al. Protective effects of tumor necrosis factor-alpha blockade by adalimumab on articular cartilage and subchondral bone in a rat model of osteoarthritis[J].Braz J Med Biol Res, 2015, 48(10): 863-870.
|
| [7] |
崔洋, 王伊伦, 魏捷, 等. 骨关节炎研究年度进展 2024[J].中华医学杂志, 2025, 105(21): 1757-1762.
|
| [8] |
Ossendorff R, Grad S, Stoddart MJ, et al. Autologous chondrocyte implantation in osteoarthritic surroundings: TNFalpha and its inhibition by adalimumab in a knee-specific bioreactor[J].Am J Sports Med, 2018, 46(2): 431-440.
|
| [9] |
Aitken D, Laslett LL, Pan F, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial[J].Osteoarthritis Cartilage, 2018, 26(7): 880-887.
|
| [10] |
Chevalier X, Ravaud P, Maheu E, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial[J].Ann Rheum Dis, 2015, 74(9): 1697-1705.
|
| [11] |
Guo P, Gao X, Nelson AL, et al. TIPE2 gene transfer ameliorates aging-associated osteoarthritis in a progenia mouse model by reducing inflammation and cellular senescence[J].Mol Ther, 2024, 32(9): 3101-3113.
|
| [12] |
Wen ZH, Tang CC, Lin YY, et al. Effects of etanercept on experimental osteoarthritis in rats: role of histone deacetylases[J].Cartilage, 2024: 19476035241264012. doi: 10.1177/19476035241264012.
|
| [13] |
Campos Y, Fuentes G, Almirall A, et al. The incorporation of etanercept into a porous tri-layer scaffold for restoring and repairing cartilage tissue[J].Pharmaceutics, 2022, 14(2): 282.
|
| [14] |
Kloppenburg M, Ramonda R, Bobacz K, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial[J].Ann Rheum Dis, 2018, 77(12): 1757-1764.
|
| [15] |
Lacy SE, Wu C, Ambrosi DJ, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta[J].MAbs, 2015, 7(3): 605-619.
|
| [16] |
de Oliveira CM, Sakata RK, Issy AM, et al. Cytokines and pain[J].Rev Bras Anestesiol, 2011, 61(2): 255-259.
|
| [17] |
Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis[J].Nat Rev Rheumatol, 2011, 7(1): 33-42.
|
| [18] |
Kamath RV, Simler G, Zhou C, et al. Blockade of both IL-1A and IL-1B by a combination of monoclonal antibodies prevents the development and reverses established pain in a preclinical model of osteoarthritis[J].Osteoarthritis Cartilage, 2012, 20: S62.
|
| [19] |
Zhang P, Zhong ZH, Yu HT, et al. Exogenous expression of IL-1Ra and TGF-beta1 promotes in vivo repair in experimental rabbit osteoarthritis[J].Scand J Rheumatol, 2015, 44(5): 404-411.
|
| [20] |
Wang SX, Abramson SB, Attur M, et al. Safety, tolerability, and pharmacodynamics of an anti-interleukin-1alpha/beta dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study[J].Osteoarthritis Cartilage, 2017, 25(12): 1952-1961.
|
| [21] |
Kloppenburg M, Peterfy C, Haugen IK, et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1alpha and anti-interleukin-1beta dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis[J].Ann Rheum Dis, 2019, 78(3): 413-420.
|
| [22] |
Fleischmann RM, Bliddal H, Blanco FJ, et al. A phase II Trial of lutikizumab, an anti-interleukin-1alpha/beta dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis[J].Arthritis Rheumatol, 2019, 71(7): 1056-1069.
|
| [23] |
Cao Z, Li Y, Wang W, et al. Is lutikizumab, an anti-interleukin-1alpha/beta dual variable domain immunoglobulin, efficacious for osteoarthritis? Results from a bayesian network meta-analysis[J].Biomed Res Int, 2020, 2020: 9013283.
|
| [24] |
Chevalier X, Eymard F. Anti-IL-1 for the treatment of OA: dead or alive?[J].Nat Rev Rheumatol, 2019, 15(4): 191-192.
|
| [25] |
Cheleschi S, Cantarini L, Pascarelli NA, et al. Possible chondroprotective effect of canakinumab: an in vitro study on human osteoarthritic chondrocytes[J].Cytokine, 2015, 71(2): 165-172.
|
| [26] |
Clements KM, Price JS, Chambers MG, et al. Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy[J].Arthritis Rheum, 2003, 48(12): 3452-3463.
|
| [27] |
van Dalen SC, Blom AB, Sloetjes AW, et al. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis[J].Osteoarthritis Cartilage, 2017, 25(3): 385-396.
|
| [28] |
Schieker M, Conaghan PG, Mindeholm L, et al. Effects of interleukin-1beta inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial[J].Ann Intern Med, 2020, 173(7): 509-515.
|
| [29] |
Keller LE, Tait Wojno ED, Begum L, et al. Interleukin-6 neutralization and regulatory T cells are additive in chondroprotection from IL-1beta-induced inflammation[J].J Orthop Res, 2023, 41(5): 942-950.
|
| [30] |
Pearson MJ, Herndler-Brandstetter D, Tariq MA, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity[J].Sci Rep, 2017, 7(1): 3451.
|
| [31] |
Richette P, Latourte A, Sellam J, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial[J].Ann Rheum Dis, 2021, 80(3): 349-355.
|
| [32] |
Budai MM, Tozser J, Benko S.Different dynamics of NLRP3 inflammasome-mediated IL-1beta production in GM-CSF- and M-CSF-differentiated human macrophages[J].J Leukoc Biol, 2017, 101(6): 1335-1347.
|
| [33] |
Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases[J].Nat Rev Drug Discov, 2016, 16(1): 53-70.
|
| [34] |
Schett G, Bainbridge C, Berkowitz M, et al. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial[J].Lancet Rheumatol, 2020, 2(10): e623-e632.
|
| [35] |
Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab[J].Nat Rev Drug Discov, 2012, 11(5): 401-419.
|
| [36] |
Shangguan L, Ding M, Wang Y, et al. Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling[J].Regen Ther, 2024, 27: 181-190.
|
| [37] |
Ledin H, Good L, Aspenberg P. Denosumab reduces early migration in total knee replacement[J].Acta Orthop, 2017, 88(3): 255-258.
|
| [38] |
Tong W, Hu Y, Chen W, et al. Denosumab attenuates knee osteoarthritis progression by inhibiting synovial inflammation via the RANK/TRAF6/FSTL1 signalling pathway[J].Research Square, 2024, DOI:10.21203/rs.3.rs-4861749/v1.
|
| [39] |
Wittoek R, Verbruggen G, Vanhaverbeke T, et al. RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial[J].Nat Med, 2024, 30(3): 829-836.
|
| [40] |
Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors[J].Protein Sci, 2008, 17(8): 1326-1335.
|
| [41] |
Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee[J].N Engl J Med, 2010, 363(16): 1521-1531.
|
| [42] |
Carrino JA, McAlindon TE, Schnitzer TJ, et al. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab[J].Osteoarthritis Cartilage, 2023, 31(12): 1612-1626.
|
| [43] |
Berenbaum F, Blanco FJ, Guermazi A, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period[J].Ann Rheum Dis, 2020, 79(6): 800-810.
|
| [44] |
Pisetsky DS.In symptomatic knee OA, adding oral methotrexate to usual analgesia reduced pain at 6 mo[J].Ann Intern Med, 2024, 177(11): JC130.
|
| [45] |
Kingsbury SR, Tharmanathan P, Keding A, et al. Pain reduction with oral methotrexate in knee osteoarthritis: a randomized, placebo-controlled clinical trial[J].Ann Intern Med, 2024, 177(9): 1145-1156.
|
| [46] |
Zhu Z, Yu Q, Leng X, et al. Low-dose methotrexate for the treatment of inflammatory knee osteoarthritis: a randomized clinical trial[J].JAMA Intern Med, 2025, 185(7): 808-816.
|
| [47] |
Najm A, Alunno A, Gwinnutt JM, et al. Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials[J].Joint Bone Spine, 2021, 88(4): 105198.
|
| [48] |
Guermazi A, Hunter DJ, Kloppenburg M.Debate: Intra-articular steroid injections for osteoarthritis - harmful or helpful?[J].Osteoarthr Imaging, 2023, 3(3): 100163.
|
| [49] |
Kroon FPB, Kortekaas MC, Boonen A, et al. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial[J].Lancet, 2019, 394(10213): 1993-2001.
|
| [50] |
Robinson KP, Chan JJ.Colchicine in dermatology: a review[J].Australas J Dermatol, 2018, 59(4): 278-285.
|
| [51] |
Marinaki S, Skalioti C, Boletis JN. Colchicine in renal diseases: present and future[J].Curr Pharm Des, 2018, 24(6): 675-683.
|
| [52] |
Dossing A, Henriksen M, Ellegaard K, et al. Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial[J].Lancet Rheumatol, 2023, 5(5): e254-e262.
|
| [53] |
Heijman MWJ, Fiolet ATL, Mosterd A, et al. Association of low-dose colchicine with incidence of knee and hip replacements: exploratory analyses from a randomized, controlled, double-blind trial[J].Ann Intern Med, 2023, 176(6): 737-742.
|
| [54] |
Singh A, Molina-Garcia P, Hussain S, et al. Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials[J].Clin Rheumatol, 2023, 42(3): 889-902.
|
| [55] |
Lee YH.Efficacy of hydroxychloroquine for knee osteoarthritis[J].Korean J Intern Med, 2022, 37(1): 51-52.
|
| [56] |
Lee W, Ruijgrok L, Boxma-de Klerk B, et al. Efficacy of Hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial[J].Arthritis Care Res (Hoboken), 2018, 70(9): 1320-1325.
|
| [57] |
Kingsbury SR, Tharmanathan P, Keding A, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial[J].Ann Intern Med, 2018, 168(6): 385-395.
|
| [58] |
Carneiro DC, Araujo LT, Santos GC, et al. Clinical trials with mesenchymal stem cell therapies for osteoarthritis: challenges in the regeneration of articular cartilage[J].Int J Mol Sci, 2023, 24(12): 9939.
|
| [59] |
De Bari C, Roelofs AJ. Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis[J].Curr Opin Pharmacol, 2018, 40: 74-80.
|
| [60] |
Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair[J].Nat Rev Rheumatol, 2013, 9(10): 584-594.
|
| [61] |
Pang Q, Zhan J, Chen Z, et al. Emerging therapy in osteoarthritis: mesenchymal stem cells, secretomes, and using hydrogels to enhance efficacy[J].BioDrugs, 2025, 39(4): 555-571.
|
| [62] |
Xing D, Zhao Y, Dong S, et al. Global research trends in stem cells for osteoarthritis: a bibliometric and visualized study[J].Int J Rheum Dis, 2018, 21(7): 1372-1384.
|
| [63] |
Whittle SL, Johnston RV, McDonald S, et al. Stem cell injections for osteoarthritis of the knee[J].Cochrane Database Syst Rev, 2025, 4(4): CD013342.
|
| [64] |
Mautner K, Gottschalk M, Boden SD, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial[J].Nat Med, 2023, 29(12): 3120-3126.
|
| [65] |
Tiwari SK, Wong WJ, Moreira M, et al. Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease[J].Nat Rev Immunol, 2025, 25(2): 108-124.
|
| [66] |
Craft AM, Rockel JS, Nartiss Y, et al. Generation of articular chondrocytes from human pluripotent stem cells[J].Nat Biotechnol, 2015, 33(6): 638-645.
|
| [67] |
Kelly K, Bloor AJC, Griffin JE, et al. Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease[J].Nat Med, 2024, 30(6): 1556-1558.
|
| [68] |
Liang C, Wu S, Xia G, et al. Engineered M2a macrophages for the treatment of osteoarthritis[J].Front Immunol, 2022, 13: 1054938.
|
| [69] |
Li X, Shen L, Deng Z, et al. New treatment for osteoarthritis: gene therapy[J].Precis Clin Med, 2023, 6(2): pbad014.
|
| [70] |
Zhou K, Yuan M, Sun J, et al. Co-delivery of IL-1Ra and SOX9 via AAV inhibits inflammation and promotes cartilage repair in surgically induced osteoarthritis animal models[J].Gene Ther, 2025, 32(3): 211-222.
|
| [71] |
De la Vega RE, Sellon JL, Smith J, et al. A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint[J].Sci Transl Med, 2025, 17(801): eadu9804.
|
| [72] |
Zhao L, Huang J, Fan Y, et al. Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis[J].Ann Rheum Dis, 2019, 78(5): 676-682.
|
| [73] |
Grigsby E, Rickam M, Thewlis D, et al. XT-150-A novel immunomodulatory gene therapy for osteoarthritis pain in phase 2b development[J].Osteoarthritis Cartilage, 2021, 29: S12.
|
| [74] |
Huang H, Zheng S, Wu J, et al. Opsonization inveigles macrophages engulfing carrier-free Bilirubin/JPH203 nanoparticles to suppress inflammation for osteoarthritis therapy[J].Adv Sci (Weinh), 2024, 11(22): e2400713.
|
| [75] |
Yan Y, Lu A, Dou Y, et al. Nanomedicines reprogram synovial macrophages by scavenging nitric oxide and silencing CA9 in progressive osteoarthritis[J].Adv Sci (Weinh), 2023, 10(11): e2207490.
|
| [76] |
Li B, Cui L, Kong K, et al. LNP-mRNA delivers TNF-α antibody to deep cartilage and protects against osteoarthritis[J].Chem Eng J, 2024, 500: 156723.
|
| [77] |
Chen H, Chen F, Hu F, et al. MicroRNA-224-5p nanoparticles balance homeostasis via inhibiting cartilage degeneration and synovial inflammation for synergistic alleviation of osteoarthritis[J].Acta Biomater, 2023, 167: 401-415.
|
| [78] |
Huang X, Li A, Xu P, et al. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles[J].J Nanobiotechnology, 2023, 21(1): 184.
|
| [79] |
Yang Z, Shi J, Xie J, et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation[J].Nat Biomed Eng, 2020, 4(1): 69-83.
|
| [80] |
Drohat P, Baron M, Kaplan LD, et al. Long-acting extracellular vesicle-based biologics in osteoarthritis immunotherapy[J].Bioengineering (Basel), 2025, 12(5): 525.
|
| [81] |
Liang Y, Xu X, Xu L, et al. Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment[J].Theranostics, 2022, 12(11): 4866-4878.
|
| [82] |
Zhang B, Tian X, Qu Z, et al. Hypoxia-preconditioned extracellular vesicles from mesenchymal stem cells improve cartilage repair in osteoarthritis[J].Membranes (Basel), 2022, 12(2): 225.
|
基金资助
甘肃省卫生健康行业科研项目(GSWSKY2024-55)